Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
Oncology
|
March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
C N Sternberg, P Whelan, J Hetherington, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
C N Sternberg, F Saad, J N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Prostate Cancer and Prostatic Diseases
|
January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
A H Bryce, J J Alumkal, A Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
British Journal of Cancer
|
February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
C-F Xu, T Johnson, J Garcia-Donas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
Oncology
|
March 3, 2005
Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer
C N Sternberg, P Whelan, J Hetherington, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 22, 2020
A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer
C N Sternberg, F Saad, J N Graff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 30, 2017
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
J Bellmunt, B J Eigl, E Senkus, et al.
Prostate Cancer and Prostatic Diseases
|
January 25, 2017
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
A H Bryce, J J Alumkal, A Armstrong, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 1, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A Jayaram, A Wingate, D Wetterskog, et al.
British Journal of Cancer
|
February 20, 2015
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
C-F Xu, T Johnson, J Garcia-Donas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 24, 2017
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
K Fizazi, A Ulys, L Sengeløv, et al.
World Journal of Urology
|
June 26, 2016
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer
M N Pham, A B Apolo, M De Santis, et al.
Page
of 13